MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus

[1]  V. Lowe,et al.  Remission of disseminated cancer after systemic oncolytic virotherapy. , 2014, Mayo Clinic proceedings.

[2]  R. Cattaneo,et al.  New viruses for cancer therapy: meeting clinical needs , 2013, Nature Reviews Microbiology.

[3]  C. von Kalle,et al.  Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. , 2013, Human gene therapy.

[4]  A. Enk,et al.  Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. , 2013, The Journal of investigative dermatology.

[5]  A. Plückthun,et al.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  S. Jäämaa,et al.  MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver , 2013, PloS one.

[7]  R. Cattaneo,et al.  Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins , 2012, Cancer Gene Therapy.

[8]  Xiaoliu Zhang,et al.  Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Carfi,et al.  Targeted entry of enveloped viruses: measles and herpes simplex virus I. , 2012, Current opinion in virology.

[10]  R. Cattaneo,et al.  Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Filip Pattyn,et al.  The microRNA body map: dissecting microRNA function through integrative genomics , 2011, Nucleic acids research.

[12]  E. Rieber,et al.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer , 2011, Cancer Gene Therapy.

[13]  C. von Kalle,et al.  MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  T. Fujiwara,et al.  Enhanced Safety Profiles of the Telomerase-Specific Replication- Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences , 2011, Clinical Cancer Research.

[15]  E. Izaurralde,et al.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay , 2011, Nature Reviews Genetics.

[16]  K. Cichutek,et al.  Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. , 2010, Cancer research.

[17]  R. Cattaneo,et al.  Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics , 2010, Gene Therapy.

[18]  L. Hartmann,et al.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. , 2010, Cancer research.

[19]  S. Russell,et al.  Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting , 2009, Journal of Virology.

[20]  K. Ghoshal,et al.  MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib* , 2009, The Journal of Biological Chemistry.

[21]  P. Rennie,et al.  MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells , 2009, Clinical Cancer Research.

[22]  S. Russell,et al.  Engineering microRNA responsiveness to decrease virus pathogenicity , 2008, Nature Medicine.

[23]  C. Croce,et al.  MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[24]  R. Andino,et al.  Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA , 2008, Journal of Virology.

[25]  H. Atkins,et al.  A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. Dingli,et al.  Preclinical Pharmacology and Toxicology of Intravenous MV‐NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide , 2007, Clinical pharmacology and therapeutics.

[27]  Yi-Hsuan Chen,et al.  miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes , 2007, Nucleic Acids Res..

[28]  R. Cattaneo,et al.  Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. , 2007, Cancer research.

[29]  R. Cattaneo,et al.  An immunocompetent murine model for oncolysis with an armed and targeted measles virus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[31]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[32]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[33]  K. Ghoshal,et al.  Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas , 2006, Journal of cellular biochemistry.

[34]  C. Sander,et al.  miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1 , 2004, RNA biology.

[35]  M. Billeter,et al.  Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.

[36]  J. Hardwick,et al.  Apoptosis as a cause of death in measles virus-infected cells , 1995, Journal of virology.

[37]  R Buckland,et al.  Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. , 1991, The Journal of general virology.

[38]  U. Lauer,et al.  Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. , 2012, Methods in molecular biology.

[39]  W. P. Duprex,et al.  The measles virus replication cycle. , 2009, Current topics in microbiology and immunology.

[40]  R. Ortíz-López,et al.  Oncolytic virotherapy. , 2008, Annals of hepatology.

[41]  R. Buckland,et al.  Functional aspects of envelope-associated measles virus proteins. , 1995, Current topics in microbiology and immunology.